Vol 1, No 2 (2005)
Review paper
Published online: 2005-06-08
Mantle cell lymphoma - novel therapeutic options
Onkol. Prak. Klin 2005;1(2):96-108.
Abstract
Mantle cell lymphoma is associated with the worst prognosis among malignant lymphomas. Standard
chemotherapy is not effective and median survival of 5 years is about 25%. Intensified induction regimens
lead to higher initial response rate, but the overall survival is unchanged.
Induction chemotherapy combined with rituximab may prolong time to progression and overall survival. High dose chemotherapy followed by autologous stem cell transplantation in first remission is associated with the best disease free and overall survival reported to date. Among available treatment options high dose chemotherapy should be considered standard approach in young patients. However its definite role should be confirmed in randomized clinical trials. In addition the role of molecular remission and maintenance therapy with monoclonal antibodies should be established.
Induction chemotherapy combined with rituximab may prolong time to progression and overall survival. High dose chemotherapy followed by autologous stem cell transplantation in first remission is associated with the best disease free and overall survival reported to date. Among available treatment options high dose chemotherapy should be considered standard approach in young patients. However its definite role should be confirmed in randomized clinical trials. In addition the role of molecular remission and maintenance therapy with monoclonal antibodies should be established.
Keywords: mantle cell lymphomainduction chemotherapyhigh-dose chemotherapy and stem cell transplantationmaintenance therapyrituximab